MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer

Cathy A. Andorfer, Brian M. Necela, E Aubrey Thompson, Edith A. Perez

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Recognition that breast cancer is a heterogeneous disease in which each patient's tumor has specific characteristics has led to a search for biomarkers and combinations of markers (signatures) to improve the diagnosis, prognostic classification and prediction of therapeutic benefit versus toxicity for individual tumors and patients. Many microRNAs (miRNAs) are aberrantly expressed in cancer and seem to influence tumor behavior and progression. miRNAs have great potential to evolve into effective biomarkers in the clinic because of their extreme stability and ease of detection. However, there are several major technical challenges as well as numerous discrepancies among currently reported miRNA signatures. In this review, we discuss the use of miRNA signatures for breast cancer treatment and discuss the challenges in the field.

Original languageEnglish (US)
Pages (from-to)313-319
Number of pages7
JournalTrends in Molecular Medicine
Volume17
Issue number6
DOIs
StatePublished - Jun 2011

Fingerprint

MicroRNAs
Biomarkers
Breast Neoplasms
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

MicroRNA signatures : Clinical biomarkers for the diagnosis and treatment of breast cancer. / Andorfer, Cathy A.; Necela, Brian M.; Thompson, E Aubrey; Perez, Edith A.

In: Trends in Molecular Medicine, Vol. 17, No. 6, 06.2011, p. 313-319.

Research output: Contribution to journalArticle

Andorfer, Cathy A. ; Necela, Brian M. ; Thompson, E Aubrey ; Perez, Edith A. / MicroRNA signatures : Clinical biomarkers for the diagnosis and treatment of breast cancer. In: Trends in Molecular Medicine. 2011 ; Vol. 17, No. 6. pp. 313-319.
@article{ed670393e965427b85fbefd5698b20ad,
title = "MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer",
abstract = "Recognition that breast cancer is a heterogeneous disease in which each patient's tumor has specific characteristics has led to a search for biomarkers and combinations of markers (signatures) to improve the diagnosis, prognostic classification and prediction of therapeutic benefit versus toxicity for individual tumors and patients. Many microRNAs (miRNAs) are aberrantly expressed in cancer and seem to influence tumor behavior and progression. miRNAs have great potential to evolve into effective biomarkers in the clinic because of their extreme stability and ease of detection. However, there are several major technical challenges as well as numerous discrepancies among currently reported miRNA signatures. In this review, we discuss the use of miRNA signatures for breast cancer treatment and discuss the challenges in the field.",
author = "Andorfer, {Cathy A.} and Necela, {Brian M.} and Thompson, {E Aubrey} and Perez, {Edith A.}",
year = "2011",
month = "6",
doi = "10.1016/j.molmed.2011.01.006",
language = "English (US)",
volume = "17",
pages = "313--319",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - MicroRNA signatures

T2 - Clinical biomarkers for the diagnosis and treatment of breast cancer

AU - Andorfer, Cathy A.

AU - Necela, Brian M.

AU - Thompson, E Aubrey

AU - Perez, Edith A.

PY - 2011/6

Y1 - 2011/6

N2 - Recognition that breast cancer is a heterogeneous disease in which each patient's tumor has specific characteristics has led to a search for biomarkers and combinations of markers (signatures) to improve the diagnosis, prognostic classification and prediction of therapeutic benefit versus toxicity for individual tumors and patients. Many microRNAs (miRNAs) are aberrantly expressed in cancer and seem to influence tumor behavior and progression. miRNAs have great potential to evolve into effective biomarkers in the clinic because of their extreme stability and ease of detection. However, there are several major technical challenges as well as numerous discrepancies among currently reported miRNA signatures. In this review, we discuss the use of miRNA signatures for breast cancer treatment and discuss the challenges in the field.

AB - Recognition that breast cancer is a heterogeneous disease in which each patient's tumor has specific characteristics has led to a search for biomarkers and combinations of markers (signatures) to improve the diagnosis, prognostic classification and prediction of therapeutic benefit versus toxicity for individual tumors and patients. Many microRNAs (miRNAs) are aberrantly expressed in cancer and seem to influence tumor behavior and progression. miRNAs have great potential to evolve into effective biomarkers in the clinic because of their extreme stability and ease of detection. However, there are several major technical challenges as well as numerous discrepancies among currently reported miRNA signatures. In this review, we discuss the use of miRNA signatures for breast cancer treatment and discuss the challenges in the field.

UR - http://www.scopus.com/inward/record.url?scp=79958767367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958767367&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2011.01.006

DO - 10.1016/j.molmed.2011.01.006

M3 - Article

C2 - 21376668

AN - SCOPUS:79958767367

VL - 17

SP - 313

EP - 319

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 6

ER -